Takeda Pharmaceutical Company Limited (TAK) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much for joining FY2025Q4 Learning School for Takeda Pharmaceutical Company. An O'Reilly IR head, I will serve as MC. First, language setting. For those of you who wish to listen to this call in English, please select English in the Zoom language select button. Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results made different materially from those discussed today. The factors that could cause actual results to differ materially are discussed in our most recent Form 20F and in our other SEC findings. And please also refer to the important notice of page 2. We may also refer to non-IFRS financial numbers for the definition and consultation. Please refer to the appendix in the presentation. Now let's start today's presentation. President and CEO Christoph Weber, CEO-elect Juleke, Chief Financial Officer Milano Furuta, R&D President Andy Plant. They will be presenting, followed by Q&A session. Let's start. Thank you, Chris, and good morning, good afternoon, and good evening, everyone. Thank you for joining us today for Takeda year-end earning call. Today will be my last earning call as President and CEO of Takeda. It has been a real privilege to serve over the past 12 years. During that time, Takeda has transformed into a company with a global scale, a strong portfolio of life-transforming medicines, and an innovative late-stage pipeline with significant potential. I'm incredibly proud of what we have accomplished together with our colleagues around the world, building Takeda into a focused, global, R&D-driven biopharmaceutical leader, consistently delivering on our financial commitment, advancing our pipeline, and crea...